About Cellective BioTherapy
Cellective BioTherapy is a Healthcare company based in Durham (United States) founded in 2015. It operates as a b cell-based therapies are developed for autoimmunity, immunodeficiency, and cancers. Cellective BioTherapy has raised $2.5 million across 1 funding round from investors including Eshelman Ventures. Its focus areas include Diversified Pharmaceuticals, Life Sciences, Immunotherapy and Adoptive Cell Therapy. Its competitors include Be Bio, Immusoft, JW Therapeutics, Walking Fish Therapeutics and Overland Pharmaceuticals; 4 of its 5 listed competitors have raised funding.
Company details
Cellective BioTherapy was founded in 2015 and is based in Durham, United States. Operations center on the biotechnology sector, where B cell-based cellular therapies are developed to address cancers, autoimmunity, and immunodeficiency. Human B cells are expanded ex vivo through proprietary technology for autologous immunotherapy applications, including treatments for immunodeficiency. The companys domain is cellectivebiotherapy.com.
- Headquarters Durham, United States
- SectorsHealthcare
- Email••••••••
- Website cellectivebiotherapy.com
- Social LinkedIn
- Total Equity Funding$2.5M (USD)
in 1 rounds
- Latest Funding Round$2.5M (USD), Seed
May 2015
- Investors
Funding Insights of Cellective BioTherapy
Cellective BioTherapy has successfully raised a total of $2.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $2.5 million completed in May 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.5M
- Total Rounds 1
- Last Round Seed — $2.5M
- First Round $2.5M
(May 2015)
- Investors Count 1
All 1 funding rounds of Cellective BioTherapy with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2015 | $2.5M | Seed | – | Eshelman Ventures | – |
1 investors in total: 1 institutional.
Investors in Cellective BioTherapy
Cellective BioTherapy has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Eshelman Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | eshelmanventures.com | - |
Investor details for Cellective BioTherapy
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cellective BioTherapy
7 people are tracked at Cellective BioTherapy (2 in leadership, 4 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Thomas F. Tedder | Founder, CEO & Director | Leadership |
Robert Bonczek | Chief Financial Officer & Director | Leadership |
Seth Rudnick | Advisor | Board & advisors |
Sailash Patel | Advisor | Board & advisors |
Fred Eshelman | Chairman | Board & advisors |
George Koszalka | Advisor | Board & advisors |
Bud Nelson | General IP Counsel | Team |
Complete people profiles for Cellective BioTherapy
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cellective BioTherapy
2 dated milestones of Cellective BioTherapy, from founding to its latest funding, stage changes and deals.
- Founded Cellective BioTherapy is founded.
- Funding First funding round of $2.5M.
Competitors of Cellective BioTherapy
Cellective BioTherapy has 5 listed competitors in our database, 4 of them funded. They include Be Bio, Immusoft, JW Therapeutics, Walking Fish Therapeutics and Overland Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| be.bio | 2020 | Cambridge, United States | $356M | – | B cell therapies are developed for oncology and rare diseases. | |
| immusoft.com | 2009 | Seattle, United States | $44.13M | – | B cells are programmed as biofactories for therapeutic protein delivery. | |
| jwtherapeutics.com | 2016 | Shanghai, China | $195.55M | – | Cell immunotherapy products are developed for cancer treatment. | |
| walkingfishtx.com | 2019 | San Francisco, United States | $123M | – | Cell-based therapeutics for cancer and immunological disorders are developed. | |
| overlandpharma.com | 2020 | Boston, United States | – | – | - |
Detailed competitors of Cellective BioTherapy
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
10 companies that operate in the same segment as Cellective BioTherapy (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cellective Biotherapy
Complete news archive for Cellective BioTherapy
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellective BioTherapy
Cellective BioTherapy was founded in 2015.
Cellective BioTherapy is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Cellective BioTherapy is a funded company, having raised a total of $2.5M across 1 funding round to date. The company's 1st funding round was a Seed of $2.5M, raised on May 2015.
Cellective BioTherapy was founded in 2015 and is based in Durham, United States. Operations center on the biotechnology sector, where B cell-based cellular therapies are developed to address cancers, autoimmunity, and immunodeficiency. Human B cells are expanded ex vivo through proprietary technology for autologous immunotherapy applications, including treatments for immunodeficiency. The companys domain is cellectivebiotherapy.com.
Cellective BioTherapy's top competitors include Be Bio, Immusoft and JW Therapeutics.
Cellective BioTherapy has 1 investor. Key investors include Eshelman Ventures.